Clinical Trial Update: PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating a PD-1 antibody in combination with neoadjuvant chemotherapy for ovarian cancer; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• PD-1 antibody (PD-1 inhibitor)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Ovarian Cancer, Neoadjuvant Chemotherapy | Phase 2 | Status: UNKNOWN